Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption

Core Insights - Veeva Systems' latest report indicates that targeted pre-launch scientific outreach significantly enhances the impact of medical affairs teams on treatment adoption, with biopharmas investing in these activities achieving 40% faster adoption rates compared to those that invest less [1][6]. Group 1: Pre-launch Scientific Outreach - Companies that engage key experts at congresses, develop clinical guidelines, and secure publication coverage before product launch experience a 40% faster treatment adoption [6]. - Investment in pre-launch congress activities has the strongest influence on treatment decisions post-approval, surpassing the impact of clinical guidelines and publications [6]. - Engaging early-career healthcare professionals (HCPs) is crucial, as they are four times more likely to initiate patients on new treatments and significantly more active in congress participation and digital engagement [6]. Group 2: Influence of Congresses and Early-career Experts - Congresses and the subsequent digital discussions are pivotal in increasing scientific awareness and facilitating impactful medical conversations [5][6]. - Early-career HCPs are five times more likely to speak at congresses, eleven times more likely to engage digitally, and seven times more likely to publish their findings [6]. - The analysis is based on over 600 million HCP interactions and activities from more than 80% of commercial biopharma field teams globally, making it a comprehensive industry benchmark [9].